Skip to main content

Table 1 Patient, disease, and treatment characteristics (N = 65)

From: Patient-reported quality-of-life outcomes in relation to provider-assessed adverse events during head and neck radiotherapy

Age Mean (SD) 65.3 (12.6)    No. (%)
    Staging Stage I 6 (9.2)
Radiation Dose Median (Range) in Gy 60 (50–70)   Stage II 9 (13.8)
    Stage III 10 (15.4)
  No. (%)   Stage IV 39 (60.0)
Sex Male 52 (80.0)   Recurrent 12 (18.5)
Female 13 (20.0)    
   Primary Site Oral cavity/oropharynx 28 (43.1)
Race White 60 (92.3)   Larynx 8 (12.3)
Black 2 (3.1)   Salivary gland 7 (10.8)
Asian 1 (1.5)   Skin 6 (9.2)
Pacific Islander 1 (1.5)   Nasopharynx 5 (7.7)
AI/AN 1 (1.5)   Nasal cavity/paranasal sinus 4 (6.2)
    Other 7 (10.8)
Treatment Type Adjuvant CCRT 21 (32.3)    
Adjuvant RT 20 (30.8) Histology Squamous cell carcinoma 51 (78.5)
Definitive CCRT 19 (29.2)   Spindle cell carcinoma 2 (3.1)
Definitive RT 5 (7.7)   Papillary thyroid carcinoma 2 (3.1)
    Melanoma 2 (3.1)
Chemotherapy Cisplatin 25 (38.5)   Merkel cell carcinoma 2 (3.1)
Cetuximab 8 (12.3)   Adenocarcinoma 2 (3.1)
Carboplatin 5 (7.7)   Other 4 (6.2)
Other 2 (3.1)    
  1. Abbreviations: AI/AN, American Indian/Alaska Native; CCRT, concurrent chemoradiotherapy; RT, radiotherapy
  2. Note: Race was self-identified. Percentages do not add to 100 because of rounding